Suppr超能文献

屋尘螨皮下免疫疗法用于中国过敏性哮喘和鼻炎患者

House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis.

作者信息

Feng Mulin, Zeng Xiaohui, Li Jing

机构信息

Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China.

出版信息

J Thorac Dis. 2019 Aug;11(8):3616-3625. doi: 10.21037/jtd.2019.06.35.

Abstract

The efficacy of allergen immunotherapy (AIT) has been reported with different allergens including house dust mites (HDM). HDM are the most prevalent allergens in patients with asthma and/or rhinitis in China. In addition to improving symptoms, reducing medication need, and improving quality of life, AIT can change the course of allergic disease and induce allergen-specific immune tolerance. To date, the use of AIT is becoming more acceptable in China, and there are many studies about the current clinical practice immunotherapy. In this paper we discuss the main aspects of AIT undertaken in China; including symptom and medication scores, pulmonary function and airway hyperresponsiveness, specific allergen sensitivity, safety evaluation, and mechanisms underlying AIT. This review will provide some important information on AIT treatment strategies to doctors, healthcare professionals and organizations involved in the AIT in China. According to the studies in China, successful AIT may induce antibody responses and cellular reactions in relation to the significant improvement in clinical symptoms, reducing the need for medications and maintenance of stable pulmonary functions.

摘要

变应原免疫疗法(AIT)对包括屋尘螨(HDM)在内的不同变应原已显示出疗效。在中国,HDM是哮喘和/或鼻炎患者中最常见的变应原。除了改善症状、减少药物需求和提高生活质量外,AIT还可以改变过敏性疾病的进程并诱导变应原特异性免疫耐受。目前,AIT在中国越来越被认可,并且有许多关于当前临床实践免疫疗法的研究。在本文中,我们讨论了中国开展的AIT的主要方面,包括症状和药物评分、肺功能和气道高反应性、特异性变应原敏感性、安全性评估以及AIT的潜在机制。本综述将为中国参与AIT的医生、医疗保健专业人员和组织提供有关AIT治疗策略的一些重要信息。根据中国的研究,成功的AIT可能会诱导抗体反应和细胞反应,这与临床症状的显著改善、药物需求的减少以及肺功能的稳定维持有关。

相似文献

1
House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis.
J Thorac Dis. 2019 Aug;11(8):3616-3625. doi: 10.21037/jtd.2019.06.35.
2
Chinese Guideline on allergen immunotherapy for allergic rhinitis.
J Thorac Dis. 2017 Nov;9(11):4607-4650. doi: 10.21037/jtd.2017.10.112.
3
EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
Allergy. 2019 May;74(5):855-873. doi: 10.1111/all.13749.
4
Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy.
Front Immunol. 2022 Feb 7;12:786738. doi: 10.3389/fimmu.2021.786738. eCollection 2021.
6
Allergen Immunotherapy in Asthma.
Pathogens. 2021 Oct 29;10(11):1406. doi: 10.3390/pathogens10111406.
7
Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Methods Mol Biol. 2017;1559:137-168. doi: 10.1007/978-1-4939-6786-5_11.
8
Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?
Curr Treat Options Allergy. 2015;2(1):1-9. doi: 10.1007/s40521-014-0040-y.
10

引用本文的文献

1
Small airway impairment and bronchial hyperreactivity in patients with house dust mites-allergic rhinitis.
Asia Pac Allergy. 2025 Sep;15(3):140-144. doi: 10.5415/apallergy.0000000000000193. Epub 2025 Mar 17.
2
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis.
Immunotherapy. 2024;16(11):749-758. doi: 10.1080/1750743X.2024.2365619. Epub 2024 Jul 3.
4
Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update.
Allergy Asthma Immunol Res. 2022 Nov;14(6):604-652. doi: 10.4168/aair.2022.14.6.604.
5
Febuxostat Alleviates Allergic Rhinitis by Inhibiting Inflammation and Monocyte Adhesion in Human Nasal Epithelial Cells via Regulating KLF6.
Evid Based Complement Alternat Med. 2022 Sep 8;2022:9092311. doi: 10.1155/2022/9092311. eCollection 2022.

本文引用的文献

2
Chinese Guideline on allergen immunotherapy for allergic rhinitis.
J Thorac Dis. 2017 Nov;9(11):4607-4650. doi: 10.21037/jtd.2017.10.112.
3
The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East China.
Allergol Immunopathol (Madr). 2017 Nov-Dec;45(6):541-548. doi: 10.1016/j.aller.2017.04.002. Epub 2017 Jun 17.
5
Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients.
Int Arch Allergy Immunol. 2016;171(3-4):234-240. doi: 10.1159/000452333. Epub 2017 Jan 4.
6
Suppression of Immunotherapy on Group 2 Innate Lymphoid Cells in Allergic Rhinitis.
Chin Med J (Engl). 2016 Dec 5;129(23):2824-2828. doi: 10.4103/0366-6999.194642.
9
Increased Expression of miR-146a in Children With Allergic Rhinitis After Allergen-Specific Immunotherapy.
Allergy Asthma Immunol Res. 2016 Mar;8(2):132-40. doi: 10.4168/aair.2016.8.2.132. Epub 2015 Oct 22.
10
Scientific foundations of allergen-specific immunotherapy for allergic disease.
Chest. 2014 Nov;146(5):1347-1357. doi: 10.1378/chest.14-0049.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验